Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells

International Immunology

Volumn 19, Issue 12, 2007, Pages 1383-1394

  Habib Agahi, Mojtaba ^a,b   Phan, Thanh T ^a   Searle, Peter F ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

4 1BB ligand; Anergy; CD80; Co stimulation; Human T cells

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; CD137 LIGAND; CD3 ANTIBODY; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GREEN FLUORESCENT PROTEIN;

ARTICLE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CARCINOMA CELL; CLONAL ANERGY; COCULTURE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LUNG CARCINOMA; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VIRAL GENE THERAPY;

4-1BB LIGAND; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, DIFFERENTIATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL PROLIFERATION; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 36248951128     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxm106     Document Type: Article

References (53)

1. Lenschow, D. J., Walunas, T. L. and Bluestone, J. A. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14:233.
2. Krummel, M. F. and Allison, J. P. 1995. CD28 and CTLA-4 have opposing effects on the response of T-cells to stimulation. J. Exp. Med. 182:459.
3. Wang, S. and Chen, L. 2004. Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses. Microbes Infect. 6:759.
4. Shrikant, P., Khoruts, A. and Mescher, M. F. 1999. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity 11:483.
5. Greenwald, R. J., Boussiotis, V. A., Lorsbach, R. B., Abbas, A. K. and Sharpe, A. H. 2001. CTLA-4 regulates induction of anergy in vivo. Immunity 14:145.
6. Wells, A. D., Walsh, M. C., Bluestone, J. A. and Turka, L. A. 2001. Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. J. Clin. Invest. 108:895.
7. Schwartz, R. H. 1990. A cell culture model for T lymphocyte clonal anergy. Science 248:1349.
8. Gimmi, C. D., Freeman, G. J., Gribben, J. G., Gray, G. and Nadler, L. M. 1993. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl Acad. Sci. USA 90:6586.
9. Schwartz, R. H. 2003. T cell anergy. Annu. Rev. Immunol. 21:305.
10. Alderson, M. R., Smith, C. A., Tough, T. W. et al. 1994. Molecular and biological characterization of human 4-1BB and its ligand. Eur. J. Immunol. 24:2219.
11. Vinay, D. S. and Kwon, B. S. 1998. Role of 4-1BB in immune responses. Semin. Immunol. 10:481.
12. Arch, R. H. and Thompson, C. B. 1998. 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB. Mol. Cell. Biol. 18:558.
13. Takahashi, C., Mittler, R. S. and Vella, A. T. 1999. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J. Immunol. 162:5037.
14. Bertram, E. M., Lau, P. and Watts, T. H. 2002. Temporal segregation of 4-1BB versus CD28-mediated costimulation: 4-1BB ligand influences T cell numbers late in the primary response and regulates the size of the T cell memory response following influenza infection. J. Immunol. 168:3777.
15. Shuford, W. W., Klussman, K., Tritchler, D. D. et al. 1997. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 186:47.
16. Cannons, J. L., Lau, P., Ghumman, B. et al. 2001. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J. Immunol. 167:1313.
17. Bertram, E. M., Dawicki, W., Sedgmen, B., Bramson, J. L., Lynch, D. H. and Watts, T. H. 2004. A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T cell response to influenza in vivo. J. Immunol. 172:981.
18. Dawicki, W. and Watts, T. H. 2004. Expression and function of 4-1BB during CD4 versus CD8 T cell responses in vivo. Eur. J. Immunol. 34:743.
19. Tan, J. T., Whitmire, J. K., Ahmed, R., Pearson, T. C. and Larsen, C. P. 1999. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses. J. Immunol. 163:4859.
20. Kim, Y. J., Kim, S. H., Mantel, P. and Kwon, B. S. 1998. Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses. Eur. J. Immunol. 28:881.
21. Kim, Y. J., Mantel, P. L., June, C. H., Kim, S. H. and Kwon, B. S. 1999. 4-1BB costimulation promotes human T cell adhesion to fibronectin. Cell Immunol. 192:13.
22. Melero, I., Bach, N. and Chen, L. 1997. Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens. Life Sci. 60:2035.
23. Melero, I., Bach, N., Hellstrom, K. E., Aruffo, A., Mittler, R. S. and Chen, L. 1998. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: Synergy with the CD28 co-stimulatory pathway. Eur. J. Immunol. 28:1116.
24. Guinn, B. A., DeBenedette, M. A., Watts, T. H. and Berinstein, N. L. 1999. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J. Immunol. 162:5003.
25. Wilcox, R. A., Flies, D. B., Zhu, G. et al. 2002. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. 109:651.
26. Mogi, S., Sakurai, J., Kohsaka, T. et al. 2000. Tumour rejection by gene transfer of 4-1BB ligand into a CD80(+) murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumour and host cells. Immunology 101:541.
27. Miller, R. E., Jones, J., Le, T. et al. 2002. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J. Immunol. 169:1792.
28. Chen, S. H., Pham-Nguyen, K. B., Martinet, O. et al. 2000. Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. Mol. Ther. 2:39.
29. Martinet, O., Ermekova, V., Qiao, J. Q. et al. 2000. Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long-term remission of liver metastases in a mouse model. J. Natl Cancer Inst. 92:931.
30. Phan, G. Q., Yang, J. C., Sherry, R. M. et al. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100:8372.
31. Dowsing, T. and Kendall, M. J. 2007. The Northwick Park tragedy - protecting healthy volunteers in future first-in-man trials. J. Clin. Pharm. Ther. 32:203.
32. Gilligan, M. G., Knox, P., Weedon, S. et al. 1998. Adenoviral delivery of B7-1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells. Gene. Therapy 5:965.
33. Lyons, A. B. and Parish, C. R. 1994. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 171:131.
34. Lyons, A. B. 2000. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J. Immunol. Methods 243:147.
35. Linsley, P. S., Bradshaw, J., Greene, J., Peach, R., Bennett, K. L. and Mittler, R. S. 1996. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 4:535.
36. Jonuleit, H., Kuhn, U., Muller, G. et al. 1997. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27:3135.
37. Walunas, T. L., Bakker, C. Y. and Bluestone, J. A. 1996. CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 183:2541.
38. Harding, F. A., McArthur, J. G., Gross, J. A., Raulet, D. H. and Allison, J. P. 1992. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356:607.
39. Xu, G. L., Zhu, X. H., Guo, B. and Wu, Y. Z. 2004. Involvement of CTLA-4 in T-cell anergy induced by staphylococcal enterotoxin A in vitro. Mol. Immunol. 41:1.
40. Waterhouse, P., Penninger, J. M., Timms, E. et al. 1995. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270:985.
41. Lee, H. W., Nam, K. O., Park, S. J. and Kwon, B. S. 2003. 4-1BB enhances CD8+ T cell expansion by regulating cell cycle progression through changes in expression of cyclins D and E and cyclin-dependent kinase inhibitor p27kip1. Eur. J. Immunol. 33:2133.
42. Lee, H.-W., Park, S.-J., Choi, B. K., Kim, H. H., Nam, K.-O. and Kwon, B. S. 2002. 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J. Immunol. 169:4882.
43. DeBenedette, M. A., Shahinian, A., Mak, T. W. and Watts, T. H. 1997. Costimulation of CD28- T lymphocytes by 4-1BB ligand. J. Immunol. 158:551.
44. Wen, T., Bukczynski, J. and Watts, T. H. 2002. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J. Immunol. 168:4897.
45. Lewis, D. E., Merched-Sauvage, M., Goronzy, J. J., Weyand, C. M. and Vallejo, A. N. 2004. Tumor necrosis factor-alpha and CD80 modulate CD28 expression through a similar mechanism of T-cell receptor-independent inhibition of transcription. J. Biol. Chem. 279:29130.
46. Borthwick, N. J., Lowdell, M., Salmon, M. and Akbar, A. N. 2000. Loss of CD28 expression on CD8(+) T cells is induced by IL-2 receptor gamma chain signalling cytokines and type I. IFN, and increases susceptibility to activation-induced apoptosis. Int. Immunol. 12:1005.
47. Suhoski, M. M., Golovina, T. N., Aqui, N. A. et al. 2007. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol. Ther. 15:981.
48. Strome, S. E., Martin, B., Flies, D. et al. 2000. Enhanced therapeutic potential of adoptive immunotherapy by in vitro CD28/ 4-1BB costimulation of tumor-reactive T cells against a poorly immunogenic, major histocompatibility. complex class I-negative A9P melanoma. J. Immunother. 23:430.
49. May, K. F. Jr, Chen, L., Zheng, P. and Liu, Y. 2002. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res. 62:3459.
50. Li, Q., Carr, A., Ito, F., Teitz-Tennenbaum, S. and Chang, A. E. 2003. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy. Cancer Res. 63:2546.
51. Melero, I., Shuford, W. W., Newby, S. A. et al. 1997. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 3:682.
52. Bansal-Pakala, P., Jember, A. G. and Croft, M. 2001. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat. Med. 7:907.
53. Lathrop, S. K., Huddleston, C. A., Dullforce, P. A., Montfort, M. J., Weinberg, A. D., and Parker, D. C. 2004. A signal through OX40 (CD134) allows anergic, autoreactive T cells to acquire effector cell functions. J. Immunol. 172:6735.